Premium
Definitive intensity‐modulated radiotherapy concurrent with systemic therapy for oropharyngeal squamous cell carcinoma: Outcomes from an integrated regional A ustralian cancer centre
Author(s) -
Masoud Rahbari Reza,
Winkley Lauren,
Hill Jacques,
Tahir Abdul Rahim Mohammed,
McKay Michael,
Last Andrew,
Shakespeare Thomas P,
Dwyer Patrick
Publication year - 2016
Publication title -
journal of medical imaging and radiation oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 43
eISSN - 1754-9485
pISSN - 1754-9477
DOI - 10.1111/1754-9485.12432
Subject(s) - medicine , systemic therapy , radiation therapy , cancer , head and neck cancer , cohort , incidence (geometry) , referral , cancer registry , oncology , surgery , breast cancer , physics , family medicine , optics
Abstract Introduction Oropharyngeal squamous cell carcinoma ( OPSCC ) incidence has increased over the past two decades largely because of an increase in human papilloma virus ( HPV )‐related OPSCC . We report here outcomes of definitive radiation therapy for OPSCC with simultaneous integrated boost intensity‐modulated radiotherapy ( IMRT ) in a regional A ustralian cancer centre. Methods We retrospectively reviewed electronic medical records ( EMR ) of all patients treated with IMRT for head and neck cancer. We included patients who received a curative intent IMRT for OPSCC (2010–2014). Results Of 61 patients, 80% were men, and the median age was 57 years. Ninety percent of our patients received concurrent systemic therapy, and 68% were p16 positive. The median radiotherapy dose received was 70 Gy in 35 fractions. The median follow up for surviving patients was 22 months. Twenty‐four month actuarial data show that the loco‐regional recurrence free, metastasis‐free MFS , cancer‐specific ( CaSS ) and overall survival percentages were 98.3%, 92.6%, 91% and 90.3%, respectively. We did not observe grades 4 or 5 acute or late toxicities, and 10 patients (16.2%) exhibited persistent grade 3 toxicity 6 months after completing the treatment. Conclusion The results from curative IMRTs for OPSCC delivered in a regional cancer centre are comparable with results published by tertiary referral centres. A long‐term follow up of this patient cohort will continue for further analyses and comparisons with tertiary centres.